Cullen/Frost Bankers, Inc. Janux Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 173 shares of JANX stock, worth $9,082. This represents 0.0% of its overall portfolio holdings.
Number of Shares
173
Previous 169
2.37%
Holding current value
$9,082
Previous $7,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
166Shares Held
37.6MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$481 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$132 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$126 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$123 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$109 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $2.19B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...